<sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.

Endocr Oncol · 2025 · PMC12550225 · PMID 41141222

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

HRQoL analysis The HRQoL analysis, as assessed by the EORTC linear transformation of scores obtained from the QLQ-GINET21 questionnaire, revealed an overall trend of decreasing scores across PRRT cycles ( Fig. 5A ), indicative of an improvement.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;sup&gt;177&lt;/sup&gt;Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.

The sentences

<sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.